XOMA Corp DE false 0000791908 0000791908 2021-08-27 2021-08-27 0000791908 us-gaap:CommonStockMember 2021-08-27 2021-08-27 0000791908 us-gaap:SeriesAPreferredStockMember 2021-08-27 2021-08-27 0000791908 us-gaap:SeriesBPreferredStockMember 2021-08-27 2021-08-27





Washington, D.C. 20549







Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): August 27, 2021




(Exact Name of Registrant as Specified in Charter)



DELAWARE   001-39801   52-2154066
(State or Other Jurisdiction
of Incorporation)
File Number)
  (I.R.S. Employer
Identification Number)

2200 Powell Street, Suite 310, Emeryville, California 94608

(Address of Principal Executive Offices) (Zip Code)

(510) 204-7200

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)



Securities registered pursuant to Section 12(b) of the Act:


Title of each class:




Name of each exchange
on which registered:

Common Stock, $0.0075 par value   XOMA   The Nasdaq Global Market
8.625% Series A Cumulative Perpetual Preferred Stock, par value $0.05 per share   XOMAP   The Nasdaq Global Market
Depositary Shares (each representing 1/1000th interest in a share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05 per share)   XOMAO   The Nasdaq Global Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




Item 8.01.

Other Events.

XOMA US LLC, a wholly owned subsidiary of XOMA Corporation (the “Company”), continues to maintain its July 1, 2008, Amended and Restated Research, Development and Commercialization Agreement with collaboration partner Novartis for iscalimab. On August 27th 2021, Novartis shared with the Company that based upon preliminary interim analysis results of Novartis’ Phase 2b kidney transplant study with iscalimab (CIRRUS I), Novartis intended to discontinue the study. According to Novartis, the study would be discontinued due to iscalimab-based treatment being less efficacious than tacrolimus-based treatment in prevention of organ rejection in patients receiving a kidney transplant. At the same time Novartis also confirmed it is continuing all other iscalimab studies in indications other than kidney transplant, for example Sjögren’s Syndrome and Lupus Nephritis.


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: September 2, 2021     By:  

/s/ Thomas Burns

      Thomas Burns
      Senior Vice President, Finance and Chief Financial Officer